Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Agios Pharmaceuticals (AGIO) Cost of Revenue (2018 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Cost of Revenue for 8 consecutive years, with $1.3 million as the latest value for Q1 2026.

  • For Q1 2026, Cost of Revenue rose 21.57% year-over-year to $1.3 million; the TTM value through Mar 2026 reached $6.6 million, up 42.31%, while the annual FY2025 figure was $6.3 million, 52.34% up from the prior year.
  • Cost of Revenue hit $1.3 million in Q1 2026 for Agios Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.9 million in Q4 2025 and bottomed at $339000.0 in Q1 2022.
  • Average Cost of Revenue over 5 years is $965529.4, with a median of $783000.0 recorded in 2024.
  • Year-over-year, Cost of Revenue surged 154.71% in 2023 and then grew 13.18% in 2024.
  • Agios Pharmaceuticals' Cost of Revenue stood at $413000.0 in 2022, then skyrocketed by 41.89% to $586000.0 in 2023, then skyrocketed by 115.02% to $1.3 million in 2024, then skyrocketed by 49.13% to $1.9 million in 2025, then decreased by 29.8% to $1.3 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $1.3 million, $1.9 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.